CFRX Nasdaq 2019 - 12 - 09

ContraFect Corporation

CFRX | $0.05 0.0% 910K

(0.0% 1d) (0.0% 1m) (-97.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (2396.14% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 535,240
http://www.contrafect.com
Sec Filling | Patents | 24 employees

(US) ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.

antibody monoclonal antibodies infectious disease influenza treatment bloodstream injection

add to watch list Paper trade email alert is off

Press-releases

Delisting of Securities of SmileDirectClub, Inc.; Bellerophon Therapeutics, Inc.; Elys Game Technology, Corp.’; Athersys, Inc.; Borqs Technologies, Inc.; ContraFect Corporation; CohBar, Inc.; AgileThought, Inc.; Fat Projects Acquisition Corp.; Evelo Biosciences, Inc.; Troika Media Group, Inc.; Impel Pharmaceuticals Inc.; Fresh Tracks Therapeutics, Inc.; and Near Intelligence, Inc. from The Nasdaq Stock Market
Published: 2023-12-26 (Crawled : 21:00) - globenewswire.com
SDCCQ | $0.0022 63K

n/a

| -72.5% | O: -28.75% H: 40.35% C: 15.79%
NDAQ | $59.885 -0.51% 1.3M

Finance

| 4.44% | O: -0.07% H: 0.75% C: 0.69%
nasdaq media acquisition pharmaceuticals market

Global Antibiotic Resistance Market Research Report 2023-2027: Search for Alternatives to Antibiotics Creates New Goldrush
Published: 2023-10-27 (Crawled : 15:00) - prnewswire.com
SNYNF | $92.966 630

Health Technology

| -11.67% | O: -18.18% H: 0.0% C: 0.0%
JNJ | $145.405 -1.48% 7.6M

Health Technology

| -2.72% | O: -2.35% H: 0.0% C: 0.0%
SNY | $46.19 0.57% 580K

Health Technology

| -11.8% | O: -15.73% H: 0.0% C: 0.0%
ENTA 4 | $16.0 -0.93% 54K

Health Technology

| 91.35% | O: -0.36% H: 1.07% C: -0.71%
CFRX | $0.05 0.0% 910K

Health Technology

| -83.06% | O: -0.41% H: 2.04% C: -7.79%
ARDS | $0.07 100K

Health Technology

| -13.58% | O: 16.05% H: 1.06% C: -7.98%
report antibiotics research global market

ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical StudyCF-370 is the first engineered lysin therapeutic targeting Gram-negative pathogens allowed to enter a human trial
Published: 2023-10-16 (Crawled : 19:00) - biospace.com/
CFRX | $0.05 0.0% 910K

Health Technology

| -91.21% | O: 17.89% H: 0.0% C: -29.19%
cf-370 fda clearance application trial pathogens

ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development
Published: 2023-09-19 (Crawled : 12:00) - globenewswire.com
CFRX | $0.05 0.0% 910K

Health Technology

| -92.31% | O: -9.23% H: 1.69% C: -3.73%
drug conference

ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370
Published: 2023-09-18 (Crawled : 12:00) - globenewswire.com
CFRX | $0.05 0.0% 910K

Health Technology

| -91.1% | O: 15.66% H: 0.0% C: 0.0%
cf-370 fda candidate application submission

ContraFect to Present at the World Anti-Microbial Resistance Congress 2023
Published: 2023-08-28 (Crawled : 12:00) - globenewswire.com
CFRX | $0.05 0.0% 910K

Health Technology

| -93.33% | O: -0.01% H: 0.0% C: -4.25%
world